Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
Kyverna Therapeutics Announces Leadership Update, Warner Biddle Appointed As Chief Executive Officer, Succeeds Peter Maag, Who Has Resigned From His Role As Ceo And A Member Of The Board, Effective Immediately
Express News | Kyverna Therapeutics Inc - Peter Maag Resigns as CEO of Kyverna Therapeutics
Express News | Kyverna Therapeutics Inc - Appoints Warner Biddle as CEO
Press Release: Kyverna Therapeutics Announces Leadership Update
J.P. Morgan Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $33
J.P. Morgan analyst Brian Cheng maintains $Kyverna Therapeutics(KYTX.US)$ with a buy rating, and maintains the target price at $33.According to TipRanks data, the analyst has a success rate of 34.4%